“Galecto Biotech”的意思、由来-开放百科全书

The galectin-3 inhibitor, TD139, has the potential to treat many diseases due to its involvement in many key biological pathways such as cell differentiation, cell growth, and apoptosis.^[3] Galecto Biotech is using this inhibitor to treat idiopathic pulmonary fibrosis (IPF), which is a progressive, irreversible and ultimately fatal lung disease that has poor prognosis and no effective therapies.^[1]^[3]^[4] Transforming growth factor is a major mediator of fibrosis and galectin-3 expression is highly upregulated in patients with idiopathic pulmonary fibrosis.^[3] TD139 galectin-3 inhibitor, reduces the transforming growth factor (TGF)-β signalling, ultimately showing a strong anti-fibrotic potential that may provide a novel treatment for idiopathic pulmonary fibrosis.^[3]

1. ^¹{{cite journal|last=Garber|first=K|journal=Nature Biotechnology|year=2013|volume=31|issue=6|pages=481|doi=10.1038/nbt0613-481|pmid=23752421|title=Galecto Biotech.}}
2. ^{{cite web |url=https://www.bloomberg.com/research/stocks/private/snapshot.asp?privcapid=154090027 |title=Company Overview of Galecto Biotech AB |publisher=Bloomberg |accessdate=November 16, 2016}}
3. ^¹²³{{cite journal|last=MacKinnon|first=A|title=Regulation of Transforming Growth Factor-β1–driven Lung Fibrosis by Galectin-3|journal=American Journal of Respiratory and Critical Care Medicine|year=2012|volume=185|issue=5|pages=537–546|doi=10.1164/rccm.201106-0965oc|pmid=22095546|pmc=3410728}}
4. ^{{cite journal|last=Raghu|first=G|title=An official ATS/ERS/JRS/ALAT statement: idiopathic pulmonary fibrosis: evidence-based guidelines for diagnosis and management.|journal=American Journal of Respiratory and Critical Care Medicine|year=2011|volume=183|issue=6|pages=788–824|doi=10.1164/rccm.2009-040gl|pmid=21471066}}

References